Stocks Health care INAB

NASDAQ · Health care

IN8BIO, Inc. (INAB)

It posted a net loss of $18.7M. At June 30, 2026 it held $18.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

What IN8BIO, Inc. does

IN8BIO, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker INAB.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What IN8BIO, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 13, 2026
   Passive stake changed SCHEDULE 13G/A
2. August 7, 2026
   Employee stock plan registration S-8
3. August 6, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.25 versus -$1.24.
4. August 6, 2026
   Quarterly results 8-K
5. June 1, 2026
   Material agreement 8-K
6. June 1, 2026
   Securities offering prospectus 424B5
7. May 29, 2026
   Activist stake changed SCHEDULE 13D/A
8. May 18, 2026
   Shelf registration to sell securities (amended) S-3/A
9. May 7, 2026
   Form S-8 POS filing S-8 POS
10. May 7, 2026
    Form S-8 POS filing S-8 POS

Recent insider filings (Forms 3, 4 and 144): 10, the latest on May 29, 2026. Insider transactions on SEC

Insider trades

What the people running IN8BIO, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns INAB

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Emily Fairbairn 2.2% (May 29, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about INAB

What does IN8BIO, Inc. do?

IN8BIO, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker INAB.

Is IN8BIO, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $18.7M.

When did IN8BIO, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from August 13, 2026.

Similar companies

Compare INAB with

Compare INAB with any company

Follow INAB

Get an email when IN8BIO, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow INAB: get an email when it files

Where the numbers come from

Financial figures are the values IN8BIO, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.